

## Alternatives to Nifedipine in the Oral Treatment of Hypertensive Urgencies (HU)

### Summary of recent literature:

- It is important to **distinguish HU from true hypertensive emergencies** which usually require **IV** therapy (with nitroprusside, nitroglycerin, labetalol, etc.) and hospitalization. The presence of acute or ongoing end organ damage constitutes a hypertensive emergency rather than a HU.
- Asymptomatic patients with severe hypertension may not benefit from acute BP reduction and lowering BP too rapidly in patients with cardiovascular risk factors, can be harmful ( $\uparrow$  risk of MI, stroke, & mortality).
- A short period (30+ min) of **rest in a quiet, dark room** often is effective in lowering BP 15-20% & is usually recommended for initial management.
- The four oral agents most used in HU are nifedipine, clonidine, captopril, and labetalol. Literature regarding the use of oral agents is not well established.
- Concerns regarding **short acting nifedipine (Adalat)** have arisen due to association with increased AMI, CVA & mortality. Revised labeling for short acting nifedipine in the USA **recommends against its use in hypertensive crisis**. The recent report of the **JNC VI** (Nov, 1997) also cautioned against the use of nifedipine in hypertensive crisis. In practice, this concern may be greater in older individuals and those at higher risk of cardiovascular/cerebrovascular disease. As always, the risk versus benefit ratio must be considered.
- **Captopril** and **Clonidine** have been suggested as better oral alternatives to nifedipine based on the current understanding of their cardiovascular & cerebral effects. (See Table: Hypertensive Urgencies - Oral Antihypertensives)

**Table: Hypertensive Urgencies - Oral Antihypertensives**

Drug	Administration	Duration	Advantages	Disadvantages / Contraindications
<b>Captopril</b> CAPOTEN®	<b>SL/PO 3.125 - 12.5mg;</b> (up to 25mg) onset: 10-15 min (SL) 15-30 min (PO) peak effect: 60 min (SL) 1-2 h (PO)	4-8 h	•Possibly beneficial effects on cerebral autoregulation and blood flow; may favorably effect regional myocardial perfusion; reduces pre- and afterload; no fluid retention; excellent for CHF and scleroderma •SL / PO / or Crush & Chew	•Bilateral renal artery stenosis; heavy proteinuria; immunosuppressive drugs; immune-mediated diseases; pregnancy •Fine control of BP not possible. •Beware in volume depleted patients & high renin states (patients on diuretics).
<b>Clonidine</b> CATAPRES®	<b>0.05 - 0.2mg PO;</b> (e.g. initial 0.2mg, then 0.1mg q1h) onset: 30-60 min peak effect: 2-4 h  can repeat q1-2h (total dose 0.6-0.8mg)	3-12 h	•Decreases heart rate and no increase in myocardial oxygen consumption.	• <b>Sedation</b> in up to 50%; orthostatic hypotension; can dramatically decrease cerebral blood flow; avoid in CHF due to decreased cardiac output and in > than first degree heart block. •Fine control of BP not possible; profound falls reported; decrease dose if > 60y/o, recent antihypertensives, volume depletion.
<b>Labetalol</b> TRANDATE®	<b>200 - 400mg PO;</b> onset: variable (30-120min) peak effect: 3 - 4 h food increases but delays onset.	8-12 h	•Favorable cardiac and possibly CNS effects	• <b>Heart failure; reactive airway disease; second and third degree heart block;</b> no dose which will reliably lower BP within a couple of hours in the majority of patients.
<b>Nifedipine</b> ADALAT®	<b>5-10mg PO/bite &amp; swallow</b> onset: 5-20 min peak effect: 30-60 min  ☞ <b>revised labeling recommends against its use in hypertensive crisis!</b>	2-6 h	• <b>Rapid onset;</b> dilates coronary arteries and relieves spasm; usually does not decrease cardiac output.	• <b>Reflex tachycardia</b> lasting 1 h; can precipitate angina in patients with high grade stenosis; nonhomogeneous cerebral perfusion; possible increase <b>risk of MI, CVA, &amp; mortality</b> with regular nifedipine. •Fine control of BP not possible; large falls in BP after 10 mg dose .

•True Hypertensive Emergencies usually require **IV** therapy (eg. Sodium nitroprusside, Nitroglycerin, Enalaprilat, Hydralazine, Labetalol, Esmolol)

### References:

- Thach AM, Schultz PJ. Nonemergent Hypertension, New perspectives. *Advances and Updates in Cardiovascular Emergencies* 1995; 13(4):1009-1023.  
 Murphy C. Hypertensive Emergencies. *Advances and Updates in Cardiovascular Emergencies* 1995; 13(4):973-1007.  
 Hirschl MM. Guidelines for the Drug Treatment of Hypertensive Crises. *Drugs* 1995;50(6): 991-1000.  
 Micromedex Inc. Drug Data Base. Nifedipine, 1997.  
 The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). *Arch Int Med*, Nov 24,1997.  
 Aldehahab W et al. Management of hypertensive urgencies and emergencies. *J Clin Pharmacol* 1995; 35:747-62.  
 Varon J, Fromm RE. Hypertensive crises. The need for urgent management. *Postgrad med* 1996;99:189-203.